



Express Mail No.: EV913329228US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Artavanis-Tsakonis *et al.*

Confirmation No.: 8375

Application No.: 10/781,060

Group Art Unit: 1649

Filed: February 17, 2004

Examiner: Aditi Dutt

For: THERAPEUTIC AND DIAGNOSTIC
METHODS AND COMPOSITIONS BASED
ON NOTCH PROTEINS AND NUCLEIC
ACIDS

Attorney Docket No.: 7326-131

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references A11-A20 and C77-C93 listed on the attached form entitled "List of References Cited by Applicants."

Copies of references A11 and C77-C93 are submitted herewith. Copies of references A12-A20 are not submitted herewith because they are U.S. patents or U.S. Patent Application Publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, was eliminated.


Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. §1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is believed to be due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day deposit account no. 50-3013. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: November 3, 2006



Adriane M. Antler 32,605
(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY. DOCKET NO.

7326-131

APPLICATION NO.

10/781,060

APPLICANT

Artavanis-Tsakonis et al.

FILING DATE

February 17, 2004

ART UNIT

1649

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A11	11/492,497	07/24/06	Ish-Horowicz et al.	
	A12	2004/0058443	03/25/04	Artavanis-Tsakonas et al.	
	A13	2004/0242482	12/02/04	Gehring et al.	
	A14	2005/0158859	07/21/05	Artavanis-Tsakonas et al.	
	A15	6,337,387	01/08/02	Sakano et al.	
	A16	6,692,919	02/17/04	Artavanis-Tsakonas et al.	
	A17	6,703,489	03/09/04	Ish-Horowicz et al.	
	A18	6,703,491	03/09/04	Homburger et al.	
	A19	6,783,956	08/31/04	Ish-Horowicz et al.	
	A20	7,118,890	10/10/06	Ish-Horowicz et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C77	DANG et al., 2003, "Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice," <i>Oncogene</i> 22(13):1988-97	
	C78	HAYASHI et al., 2004, "Expression failure of the notch signaling system is associated with the pathogenesis of testicular germ cell tumor," <i>Tumour Biol.</i> 25(3):99-105	
	C79	HARPER et al., 2003, "Notch signaling in development and disease," <i>Clin. Genet.</i> 64(6):461-72	
	C80	HOEK et al., 2004, "Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas," <i>Cancer Res.</i> 64(15):5270-82	
	C81	KIARIS et al., 2004, "Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium," <i>Am. J. Pathol.</i> 165(2):695-705	
	C82	LI et al., 1997, "Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1," <i>Nat. Genet.</i> 16(3):243-51	
	C83	LOUVI et al., 2006 "Notch Signalling in vertebrate neural development," <i>Nature Reviews Neuroscience</i> 7(2):93-102	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD-1639385v1

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 7326-131	APPLICATION NO. 10/781,060
	APPLICANT Artavanis-Tsakonis et al.	
	FILING DATE February 17, 2004	ART UNIT 1649

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C84	ODA et al., 1997, "Mutations in the human Jagged1 gene are responsible for Alagille syndrome," Nat. Genet. 16(3):235-42	
	C85	PATEL et al., 2005, "Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function," Cancer Res. 65(19):8690-7	
	C86	PECE et al., 2004, "Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis," J. Cell. Biol. 167(2):215-21	
	C87	PUI et al., 1999, "Notch1 expression in early lymphopoiesis influences B versus T lineage determination," Immunity 11(3):299-308	
	C88	PUROW et al., 2005, "Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation," Cancer Res. 65(6):2353-63	
	C89	ROBEY et al., 1996, "An activated form of Notch influences the choice between CD4 and CD8 T cell lineages," Cell 87(3):483-92	
	C90	SANTAGATA et al., 2004, "JAGGED1 expression is associated with prostate cancer metastasis and recurrence," Cancer Res. 64(19):6854-7	
	C91	SESTAN et al., 1999, "Contact-dependent inhibition of cortical neurite growth mediated by notch signaling," Science 286(5440):741-6	
	C92	SRIURANPONG et al., 2001, "Notch signaling induces cell cycle arrest in small cell lung cancer cells," Cancer Res. 61(7):3200-5	
	C93	VEERARAGHAVALU et al., 2004, "Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in JAGGED1 and manic fringe expression linked to notch activation," J. Virol. 78(16):8687-700	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	